Trastuzumab

• A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting
  2024-514180-25-00 Phase III 14 countries Seagen Inc.
• EVIDENT Recruiting
  2023-510092-62-00 Phase II 1 country Oslo University Hospital HF
• The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: a randomized multi-center study in resectable HER2… Recruiting
  2024-513797-22-00 Phase III 1 country Amsterdam UMC Stichting
• TIME AND MOTION STUDY OF A SUBCUTANEOUS FIXED DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR THE TREATMENT OF PATIENTS WITH HER2-POSITIV… Recruiting
  2023-509321-50-00 Phase III 1 country Roche Farma S.A.
• A study of Trastuzumab Deruxtecan to assess its safety, tolerability, immune response, and inhibition of tumor activity when given alone or … Recruiting
  2023-504888-16-00 Phase I/II 5 countries AstraZeneca AB
• ProTarget - A Danish Nationwide Clinical Trial on Targeted Anti‐Cancer Treatment based on Genomic Profiling Recruiting
  2023-510527-29-00 Phase II 1 country Rigshospitalet
• LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting
  2022-502706-33-00 Phase IV 1 country Grupo Espanol De Investigacion En Cancer De Mama
• DRUP trial Recruiting
  2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-… Ended
  2024-513540-29-00 Phase III 5 countries Alliance Foundation Trials LLC
• TRAP-BTC Efficacy and safety of GemCis plus Trastuzumab plus Pembrolizumab in previously untreated HER2-positive biliary tract cancer Ended
  2023-505722-33-00 Phase II 1 country Institut fuer Klinische Krebsforschung IKF GmbH
• Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarci… Ended
  2024-513610-34-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
• DESTINY-Breast11 will compare trastuzumab deruxtecan (T-DXd) alone or in sequence with other medications, known as THP, with standard of car… Ended
  2023-505210-18-00 Phase III 4 countries AstraZeneca AB
• Multi-drug treatment for breast cancer patients with brain metastases Ended
  2024-510703-11-00 Phase II 1 country Unicancer
• A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gas… Ended
  2023-510319-20-00 Phase III 12 countries Jazz Pharmaceuticals Ireland Limited
• Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive… Ended
  2023-505249-24-00 Phase III 9 countries AstraZeneca AB
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive… Ended
  2023-503568-18-00 Phase III 14 countries F. Hoffmann-La Roche AG
• Image‐guided de‐escalation of neoadjuvant chemotherapy in HER2‐positive breast cancer: the TRAIN‐3 study Ended
  2024-516205-23-00 Phase II 1 country BOOG Study Center B.V.
• Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer after FDG-PET response-adapted strategy. The PHERGain study Ended
  2023-509923-42-00 Phase II 5 countries Medica Scientia Innovation Research S.L.
• An open-label extension study of pertuzumab administered on its own or in combination with other anti-cancer therapies in patients previousl… Ended
  2023-505102-42-00 Phase III 3 countries F. Hoffmann-La Roche AG
• PREDIX HER2 - preoperative treatment of HER2 positive breast cancer Ended
  2023-508411-23-00 Phase II 1 country Karolinska University Hospital
• Use of circulating tumor dna test to intensify post-operative treatment of patients with resected colon cancer. Halted
  2024-515152-20-00 Phase II 1 country Gruppo Oncologico Del Nord Ovest
• ELVN-002 combined with trastuzumab +/- chemotherapy in HER2 + Solid Tumors Ended
  2023-509716-29-00 Phase I/II 5 countries Enliven Therapeutics Inc.
• A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Admi… Ended
  2023-506380-33-00 Phase III 3 countries F. Hoffmann-La Roche AG
• Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program) Ended
  2024-512826-26-00 Phase II 1 country Institut Gustave Roussy

Showing 25–48 of 54 trials